Riskpilot← Back to searchSign inGet full accessLabtex Oy
OYActiveY-tunnus 2539570-7Laippatie 5Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2013— employeeswww.labtex.fi
Revenue 2025
EUR 0
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2025
EUR 0
-100% vs 2024
| Revenue | EUR 0 | — |
| EBITDA | EUR 0 | — |
| Net profit | EUR 0 | -100% |
| Total assets | EUR 0 | -100% |
| Equity | EUR 0 | -100% |
| Employees | — | — |
Legal name
Labtex Oy
Y-tunnus number
2539570-7
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
21. maaliskuuta 2013
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön päätoimialaan kuuluu terveydenhuollon laitteiden, tarvikkeiden, laboratorio- ja sairaanhoitotarvikkeiden tukkukauppa. Lisäksi toimialaan kuuluu edellä mainittujen laitteiden maahantuonti, vienti ja myynti. Lisäksi yrityksen toimialaan kuuluu edustus- ja konsultointipalvelut, sertifioinnit, markkinointi ja jakelu, koulutustoiminta ja henkilöstövuokraus. Lisäksi yrityksen toimialaan kuuluu graafisen alan painotyöt ja palvelut, kirjakustannus ja mediapalvelut.
Address
Laippatie 5
Phone
+3580505115324
Email
info@labtex.fi
Website
www.labtex.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 257 | 274 | 270 | 376 | 0 |
| Staff expenses | −37 | −42 | −44 | −45 | −0 |
| EBITDA | 15 | 48 | 0 | 50 | 0 |
| Depreciation & amort. | −0 | −0 | −0 | −1 | −0 |
| EBIT | 15 | 48 | 75 | 49 | 0 |
| Net financials | −0 | 0 | 0 | −0 | 0 |
| Profit before tax | 15 | 48 | 0 | 49 | 0 |
| Tax | 4 | 10 | −0 | 10 | −0 |
| Net profit | 11 | 38 | 0 | 39 | 0 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 147 | 176 | 14 846 | 219 | 0 |
| Equity | 92 | 123 | 0 | 121 | 0 |
| Long-term debt | — | — | 0 | 902 | 0 |
| Short-term debt | 55 | 53 | 2 604 | 98 | 0 |
| Total debt | 55 | 53 | 0 | 98 | 0 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20212025
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20212025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
TM Audit | Audit | 2022 |
HH Deputy Member | Deputy Member | 2013 |
PS Chief Executive Officer | Chief Executive Officer | 2013 |
MS Deputy auditor | Deputy auditor | 2022 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Labtex Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Timo Matti Kervinen | Audit | 0 companies |
| Hannelore Helena Riissanen | Deputy Member | 0 companies |
| Paramjit Singh | Chief Executive Officer | 0 companies |
| Martta Siiri Maria Hakala | Deputy auditor | 0 companies |